Vantage Point: Boosting Quality, Containing Costs

Shannon Armstrong
Shannon Armstrong

Last year, hospitals saw CMS's ­value-based purchasing initiative affect their adjustments for the first time—and they are taking this change seriously.  To protect their reimbursements, hospital officials are scrambling to find strategies for improving on quality measures.

But many hospitals lack the necessary data systems to make meaningful improvements in a short amount of time.  One hospital executive told GfK, “I have the best EMR system available, but I can't query 30-day re-admits.” Hospitals find themselves under extreme financial pressure as they struggle to deliver cost-effective care and perform against quality metrics.

As a result, hospitals are searching for innovative ways to boost quality and curtail costs. They are thinking through quality not just in terms of what occurs within their walls, but also the longer-term impact of choices and technologies on their patients.

Many see data as the silver bullet that can shift healthcare practice from a volume-driven business to one where quality choices lead to optimized outcomes.  As such, a whole new industry has emerged to provide analytics and predictive tools that support optimized care delivery and avoidance of error.

All stakeholders in the US health system are trying to navigate the landscape changes caused by healthcare reform and the increased use of quality-based payment systems.  Hospitals are struggling to ramp up performance on key metrics quickly, looking to a variety of data-driven tools to improve quality, systems and financial performance.  Look for more innovation in the use of health information technologies and Big Data to drive improvements in readmission and infection rates, as well as other core quality metrics.  

Shannon Armstrong is senior consultant for GfK's market access practice.

You must be a registered member of MMM to post a comment.

Next Article in Features

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters

Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.